• Contact us
  • E-Submission
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Articles

Review

Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review

Jinsoo Min1orcid , Bruno B. Andrade2,3orcid , Ju Sang Kim4orcid , Yoolwon Jeong5orcid
DOI: https://doi.org/10.12771/emj.2025.00115 [Epub ahead of print]
Published online: April 2, 2025
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Laboratory of Clinical and Translational Research, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia 40296-710, Brazil
3The BRIGHT Lab, Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Institute, Salvador, Bahia 41810-710, Brazil
4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
5Department of Preventive Medicine, Dankook University Hospital, Cheonan, of Korea
Corresponding author:  Jinsoo Min,
Email: minjinsoo@catholic.ac.kr
Yoolwon Jeong,
Email: cancerprev@dkuh.co.kr
Received: 9 March 2025   • Revised: 20 March 2025   • Accepted: 25 March 2025
  • 51 Views
  • 3 Download
  • 0 Crossref
  • 0 Scopus

Recent advancements in tuberculosis treatment research emphasize innovative strategies that enhance treatment efficacy, reduce adverse effects, and adhere to patient-centered care principles. As tuberculosis remains a significant global health challenge, integrating new and repurposed drugs presents promising avenues for more effective management, particularly against drug-resistant strains. Recently, the spectrum concept in tuberculosis infection and disease has emerged, underscoring the need for research aimed at developing treatment plans specific to each stage of the disease. The application of precision medicine to tailor treatments to individual patient profiles is crucial for addressing the diverse and complex nature of tuberculosis infections. Such personalized approaches are essential for optimizing therapeutic outcomes and improving patient adherence—both of which are vital for global tuberculosis eradication efforts. The role of tuberculosis cohort studies is also emphasized, as they provide critical data to support the development of these tailored treatment plans and deepen our understanding of disease progression and treatment response. To advance these innovations, a robust TB policy framework is required to foster the integration of research findings into practice, ensuring that treatment innovations are effectively translated into improved health outcomes worldwide.

TOP